Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Cardiol Rev. 2004 Jan-Feb;12(1):44-8.

    Glucocorticoid-remediable aldosteronism.

    Source

    Division of Endocrinology, Diabetes & Hypertension, Brigham & Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA. gmcmahon@partners.org

    Abstract

    Glucocorticoid remediable aldosteronism (GRA) appears to be the most common monogenic form of human hypertension. As a result of chimeric gene duplication, aldosterone is ectopically synthesized in the zona fasciculata of the adrenal gland under the control of adrenocorticotropin (ACTH). Affected individuals are typically hypertensive, often with onset in youth, and demonstrate refractoriness to standard antihypertensives such as angiotensin-converting enzyme inhibitors and beta-blockers. GRA subjects are normokalemic but often develop hypokalemia when treated with a potassium-wasting diuretic. Analysis of affected kindreds has demonstrated a high prevalence of early cerebral hemorrhage, largely as a result of aneurysms. Identification of affected individuals should allow direct neurovascular screening and targeted antihypertensive therapy.

    PMID:
    14667264
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Lippincott Williams & Wilkins

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk